Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain.
1 The intracarotid administration of alkylglycerols has been reported previously by us to be a novel strategy for increased delivery of various chemotherapeutic drugs to the normal brain and brain tumors in rats. 2 Effectiveness and structure-activity relations of the most promising pentyl- and hexylglycerol derivatives have been elucidated in vivo by analyzing the transfer of methotrexate (MTX) across the blood-brain barrier (BBB) in normal rats. The effects were compared with BBB disruption using hypertonic mannitol or intracarotid infusion of bradykinin. Furthermore, toxicity of the alkylglycerols has been studied in long-term experiments. 3 Apart from 1-O-pentyldiglycerol, all alkylglycerols induced a concentration-dependent increase in MTX delivery to the brain varying from 1.1 to more than 300-fold compared to intra-arterial MTX alone. Enhanced barrier permeability rapidly approached baseline values within 5 and 120 min at the latest. Chemical structure, concentration, time schedule of injections and combination of different alkylglycerols were identified as instruments suited to regulate the MTX accumulation within a wide range. Mannitol 1.4 M resulted in very high MTX levels in the brain as observed using the highest concentrations of alkylglycerols. Intracarotid infusion of bradykinin had only a minor effect on the BBB. Using 1-O-pentylglycerol or 2-O-hexyldiglycerol, both cell culture experiments and long-term in vivo analyses including clinical, laboratory and histopathological evaluations revealed no signs of toxicity. 4 In summary, intracarotid short-chain alkylglycerols constitute a very effective and low toxic strategy for transient opening of the BBB to overcome the limited access of cytotoxic drugs to the brain.
Erdlenbruch
Bernhard
B
Universitätskinderklinik Göttingen, Robert-Koch-Str. 40, D-37075 Göttingen, Germany. erdlenbr@med.uni-gottingen.de
Schinkhof
Claudia
C
Kugler
Wilfried
W
Heinemann
Dagmar E H
DE
Herms
Jochen
J
Eibl
Hansjörg
H
Lakomek
Max
M
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000503:physiopathology; D001920:Bradykinin / Q000008:administration & dosage / Q000493:pharmacokinetics; D001921:Brain / Q000187:drug effects* / Q000378:metabolism* / Q000648:ultrastructure; D002339:Carotid Arteries; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005990:Glycerol / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*; D005995:Glyceryl Ethers / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000493:pharmacokinetics; D008727:Methotrexate / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D009000:Monocytes / Q000187:drug effects; D010539:Permeability; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D013329:Structure-Activity Relationship; D013997:Time Factors; D014683:Vena Cava, Superior
C468006:1-O-pentylglycerol; D004337:Drug Carriers; D005995:Glyceryl Ethers; D008353:Mannitol; D005990:Glycerol; D001920:Bradykinin; D008727:Methotrexate